Abbott Laboratories (ABT): Price and Financial Metrics
Abbott Laboratories (ABT)
Today's Latest Price: $105.72 USD
Updated Oct 29 3:20pm
Add ABT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABT Stock Summary
- ABT has a market capitalization of $188,419,802,494 -- more than approximately 99.28% of US stocks.
- ABT's went public 34.85 years ago, making it older than 92.89% of listed US stocks we're tracking.
- Price to trailing twelve month operating cash flow for ABT is currently 29.44, higher than 86.98% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to Abbott Laboratories, a group of peers worth examining would be SHOP, CMCSA, PEP, T, and NKE.
- ABT's SEC filings can be seen here. And to visit Abbott Laboratories's official web site, go to www.abbott.com.
ABT Stock Price Chart Interactive Chart >
ABT Price/Volume Stats
| Current price | $105.72 | 52-week high | $114.19 |
| Prev. close | $106.42 | 52-week low | $61.61 |
| Day low | $104.57 | Volume | 2,697,826 |
| Day high | $106.58 | Avg. volume | 7,083,098 |
| 50-day MA | $106.46 | Dividend yield | 1.35% |
| 200-day MA | $93.84 | Market Cap | 187.18B |
Abbott Laboratories (ABT) Company Bio
Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.
ABT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $105.72 | $35.15 | -67% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Abbott Laboratories. To summarize, we found that Abbott Laboratories ranked in the 21th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for ABT, they are:
- As a business, ABT is generating more cash flow than 91.27% of positive cash flow stocks in the Healthcare.
- The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than only 22.05% of the free cash flow producing stocks we're observing.
- ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 37.98% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -68% |
| 1% | -67% |
| 2% | -67% |
| 3% | -67% |
| 4% | -66% |
| 5% | -66% |
Want more companies with a valuation profile/forecast similar to that of Abbott Laboratories? See TMO, VIVO, WST, BAX, and DHR.
Loading social stream, please wait...